These data lead to a potential therapeutic approach to liver fibrosis by combining FXR agonists with SUMOylation inhibitors, which may provide insights into how to better harness FXR as a therapeutic target for the drug development of liver fibrosis induced by various etiologies. Here, NR1H4 is linked to Hepatic fibrosis.